Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
Praxis Precision Medicines (NASDAQ:PRAX) and Remagine Labs announced a licensing and research collaboration to develop an iontophoretic transdermal patch delivering ulixacaltamide, using Remagine’s multi-day skin dosing platform. Separately, Praxis said the FDA extended a relutrigine NDA review by three months, moving the PDUFA date from Sept. 27 to Dec. 27.
How this was made
The 30-second read
Why it matters
The Remagine agreement is a development-enabling step that can broaden formulation and dosing strategy. The FDA NDA review extension for relutrigine is a concrete regulatory timing update that can affect expectations for launch readiness and valuation over the next several months.
Market read
Traders get two actionable updates: a new ulixacaltamide delivery partnership and a relutrigine NDA review timing extension to December 27.
What to watch
The FDA NDA review extension for relutrigine is a separate catalyst; traders may focus more on relutrigine’s December PDUFA timeline than on the earlier-stage delivery collaboration.
Background
Praxis is developing CNS therapies and uses proprietary platforms (Cerebrum, Solidus). The article adds a new delivery collaboration for ulixacaltamide and notes an FDA review extension for relutrigine.
Ticker impact
Praxis entered a licensing and research collaboration with Remagine Labs to develop an iontophoretic transdermal patch delivering ulixacaltamide for essential tremor.
Near-term reaction likely modest, with more meaningful repricing contingent on subsequent clinical readouts and NDA progress.
The article discloses a partnership and license agreement plus a separate FDA NDA review extension for relutrigine, but provides no trial results, timelines, or financial terms tied to ulixacaltamide.
Market effects
Highlights continued interest in transdermal delivery platforms for CNS drugs, which can support sentiment toward biotech delivery-enabling partnerships.
None indicated.
None indicated.
Counterpoint
A platform licensing deal may not translate into value until ulixacaltamide shows clinical benefit with the patch, so the market may discount it as pre-data.
Key entities
- companyPraxis Precision Medicines
NASDAQ-listed biotech subject of the licensing and research collaboration, and the FDA NDA review extension for relutrigine.
- companyRemagine Labs
Partner providing a platform for multi-day sustained skin-based dosing used for the ulixacaltamide patch program.
- drug_programUlixacaltamide
T-type calcium channel inhibitor in essential tremor development, targeted for delivery via an iontophoretic transdermal patch.
- drug_programRelutrigine
Treatment for epileptic and SCN2A/SCN8A developmental encephalopathy, with an FDA NDA review extension to a new PDUFA target date.
